Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with ...
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...
NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown ...
How can imaging biomarkers enhance our understanding of MS? Dr Anne Cross and Dr Matthew Brier examine MRI advancements that ...
With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...
Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma October 22, 2025 10:30 AM EDTCompany ...
ZNetwork on MSNOpinion
The Fourth Branch: How Conscience and Civic Vigilance May Save the Republic
Democracy depends not just on officeholders, but on the quiet vigilance of institutional and civic actors—the novel “fourth ...
Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...
Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback